Oncospace is a software system designed to assist radiation oncologists and medical dosimetrists in planning radiotherapy treatments for prostate, thoracic, pancreas, and head & neck cancers. It uses machine learning to predict personalized dose goals for organs at risk, helping clinicians optimize treatment plans more efficiently and safely, potentially reducing the number of iterations needed for plan approval.
Oncospace is used to configure and review radiotherapy treatment plans for patients with malignant or benign disease in prostate, thoracic, pancreas, or head & neck regions. It allows setting treatment protocols, associating treatment plans, submitting dose prescriptions and dosimetric goals to treatment planning systems, and reviewing treatment plans. Intended for use by qualified radiation therapy professionals.
Oncospace is a software-only device employing locked machine learning algorithms to augment radiotherapy treatment planning by predicting individualized dosimetric goals for organs at risk based on patient-specific anatomical geometry. It integrates with existing treatment planning systems via DICOM to automate plan optimization and review, without controlling radiation delivery devices or modifying ROI contours.
Verification and validation testing showed the device met system requirements and improved planning efficiency by reducing the number of plan optimization iterations by almost two thirds compared to traditional workflows, based on retrospective clinical data across prostate, thoracic, pancreas, and head & neck cancers. Safety and effectiveness were demonstrated without adverse effects.
No predicate devices specified
Submission
8/12/2020
FDA Approval
3/12/2021
Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.
We respect your privacy. Unsubscribe at any time.